Addressing MIST (metabolites in safety testing): Bioanalytical approaches to address metabolite exposures in humans and animals

Current Drug Metabolism

Volumn 12, Issue 6, 2011, Pages 578-586

  Gao, Hongying ^a   Obach, R Scott ^a  

^a PFIZER INC   (United States)

Author keywords

Drug metabolite safety assessment; HPLC MS MS; Metabolite quantitation; MIST; Peak area ratio; Radiometric quantitation

Indexed keywords

DRUG METABOLITE;

ARTICLE; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SAFETY; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; STANDARD;

EID: 79957961908     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011795713661     Document Type: Article

References (38)

1. Baillie, T.A.; Cayen, M.N.; Fouda, H.; Gerson, R.J.; Green, J.D.; Grossman, S.J.; Klunk, L.J.; LeBlanc, B.;, Perkins, D.G.; Shipley, L.A. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol., 2002, 182, 188-196.
2. Davis-Bruno, K.L.; Atrakchi, A. A Regulatory Perspective on Issues and Approaches in Characterizing Human Metabolites. Chem. Res. Toxicol., 2006, 19, 1561-1563. (Pubitemid 44975118)
3. Robison, T.W.; Jacobs, A. Metabolites in safety testing. Bioanalysis, 2009, 1, 1193-1200.
4. Hastings, K.L.; El-Hage, J.; Jacobs, A.; Leighton, J.; Morse, D.; Osterberg, R.E. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol., 2003, 190, 91-92.
5. International Conference on Harmonization http://www.ich.org/products/ guidelines/safety/article/safetyguidelines. html (Accessed March 4, 2011.)
6. Prueksaritanont, T.; Lin, J.H.; Baillie, T.A. Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol., 2006, 217, 143-152. (Pubitemid 44780764)
7. Smith, D.A.; Obach, R.S. Metabolites and safety: what are the concerns, and how should we address them? Chem. Res. Toxicol., 2006, 19, 1570-1579. (Pubitemid 44975120)
8. Yu, H.; Bischoff, D.; Tweedie, D. Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3 (R2) guidance. Expert Opin. Drug Metab. Toxicol., 2010, 6, 1539-1549.
9. Walker, D.; Brady, J.; Dalvie, D.; Davis, J.; Dowty, M.; Duncan, J.N.; Nedderman, A.; Obach, R.S.; Wright, P. A Holistic Strategyfor Characterizing the Safety of Metabolites through Drug Discovery and Development. Chem Res Toxicol., 2009, 22, 1653-1662.
10. Ramanathan, R.; Josephs, J.L.; Jemal, M.; Arnold, M.; Humphreys, W.G. Novel MS solutions inspired by MIST. Bioanalysis, 2010, 2, 1291-1313.
11. Timmerman, P.; Kall, M.A.; Gordon, B.; Laakso, S.; Freisleben, A.; Hucker, R. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalytical Forum. Bioanalysis, 2010, 2, 1185-1194.
12. Bansal, S.; DeStefano, A. Key Elements of Bioanalytical Method Validation for Small Molecules. AAPS Journal., 2007, 9, E109- E114.
13. Frederick, C.B.; Obach, R.S. Metabolites in safety testing: "MIST" for the clinical pharmacologist. Clin. Pharmacol. Ther., 2010, 87, 345-350.
14. Park, B.K.; Pirmohamed, M.; Kitteringham, N.R. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol., 1998, 11, 969-988. (Pubitemid 28447286)
15. Smith, D.A.; Obach, R.S. Metabolites: have we MIST out the importance of structure and physicochemistry? Bioanalysis, 2010, 2, 1223-1233.
16. Lappin, G.; Seymour, M. Addressing metabolite safety during firstin- man studies using 14C-labeled drug and accelerator mass spectrometry. Bioanalysis, 2010, 2, 1315-1324.
17. Leclercq, L.; Cuyckens, F.; Mannens. S.J.G.; De Vries, R.; Timmerman, P.; Evans, D.C. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol., 2009, 22, 280-293
18. Anderson, S.; Luffer-Atlas, D.; Knadler, M.P. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol., 2009, 22, 243-256.
19. Dalvie, D.; Obach, R.S.; Kang, P.; Prakash, C.; Loi, C.M.; Hurst, S.; Nedderman. A.; Goulet, L.; Smith, E.; Bu, H.Z.; Smith, D.A. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol., 2009, 22, 357-368.
20. Hamilton, R.A.; Garnett, W.R.; Kline, B.J. Mean serum level determination by assay of a single pooled sample. Clin. Pharmacol. Ther., 1981, 29, 409-413.
21. Hop, C.E.C.A.; Wang, Z.; Chen, Q.; Kwei, G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J. Pharm. Sci., 1998, 87, 901-903. (Pubitemid 28319423)
22. Gao, H.Y.; Deng, S.B.; Obach, R.S. A simple LC/MS/MS method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments. Drug Metab. Dispos., 2010, 38, 2147-2156.
23. Ma, S., Li, Z.; Lee, K.J.; Chowdhury, S.K. Determination of Exposure Multiples of Human Metabolites for MIST Assessment in Preclinical Safety Species without Using Reference Standards or Radiolabeled Compounds. Chem. Res. Toxicol., 2010, 23, 1871-1873.
24. Dow, J.; Piriou, F.; Wolf, E.; Dulery, B.D., Haegele, K.D. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans. Drug Metab. Dispos., 1994, 22, 738-749. (Pubitemid 24307489)
25. Obach, R.S.; Reed-Hagen, A.E.; Krueger, S.S.; Obach, B.J.; O'Connell, T.N.; Zandi, K.S.; Miller, S.; Coe, J.W. Metabolism and disposition of varenicline, a selective .alpha.4.beta.2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Dispos., 2006, 34, 121-130. (Pubitemid 43042653)
26. Zhang, D.; Raghavan, N,; Chando, T.; Gambardella, J.; Fu, Y.; Zhang, D.; Unger, S.E.; Humphreys, W.G. LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Drug Metab. Lett., 2007, 1, 293-298.
27. Yi, P.; Luffer-Atlas, D. A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations. Bioanalysis, 2010, 2, 1195-1210.
28. Pauli, G.F.; Jaki, B.U.; Lankin, D.C. Quantitative 1H NMR: development and potential of a method for natural products analysis. J. Nat. Prod., 2005, 68, 133-149. (Pubitemid 40175949)
29. Dear, G.J.; Roberts, A.D.; Beaumont, C.; North, S.E. Evaluation of preparative high performance liquid chromatography and cryoprobe- nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J. Chrom. B., 2008, 876, 182-190.
30. Espina. R.; Yu, L.; Wang, J.; Tong, Z.; Vashishtha, S.; Talaat, R.; Scatina, J.; Mutlib, A. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol., 2009, 22, 299-310.
31. Vishwanathan, K.; Babalola, K.; Wang, J.; Espina, R.; Yu, L.; Adedoyin, A.; Talaat, R.; Mutlib, A.; Scatina, J. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol., 2009, 22, 311-322.
32. Walker, G.S.; Ryder, T.F.; Sharma, R.; Smith, E.B.; Freund, A. Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR. Drug Metab. Dispos., 2011, 39, 433-440.
33. Martino, R.; Malet-Martino, M.; Gilard, V. Fluorine nuclear magnetic resonance: a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr. Drug Metab., 2000, 1, 271-303.
34. Malet-Martino, M.; Gilard, V.; Desmoulin, F.; Martino, R. Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs. Clin. Chem. Acta, 2006, 366, 61-73. (Pubitemid 43330967)
35. Lenz, E.M., Wilson, I.D.; Wright, B.; Partridge, E.A.; Rodgers, E.T.; Haycock, P.R.; Lindon, J.C.; Nicholson, J.K. A comparison of quantitative NMR and radiolabelling studies on the metabolism of StatilTM (3-(4-bromo-2- fluorobenzyl)-4-oxo-3H-phthalazin-1- ylacetic acid) in the rat. J. Pharm. Biomed. Anal., 2002, 28, 31-43. (Pubitemid 34171644)
36. Viswanathan, C.T.; Bansal, S.; Booth, B.; DeStefano, A.J., Rose, M.J.; Sailstad, J.; Shah, V.P.; Skelly, J.P.; Swann, P.G.; Weiner, R. Workshop/Conference Report - Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. AAPS J., 2007, 9, E30-E42. (Pubitemid 46296546)
37. FDA Guidance for Industry www.fda.gov/downloads/Drugs/ GuidanceCompliancRegulatoryInformation/ Guidances/UCM070107.pdf (Accessed March 7, 2011)
38. Atrakchi, A.H. Interpretation and Considerations on the Safety Evaluation of Human Drug Metabolites. Chem. Res. Toxicol., 2009, 22, 1217-1220.